免费

US Patent for Treatment of cognitive impairment associated with schizophrenia Patent (Patent # 12,059,408 issued August 13, 2024)

FIELD OF THE INVENTIONThe present invention relates to a specific compound, which a GlyT1 inhibitor, and its use for the treatment of Schizophrenia and cognitive impairment associated with schizophrenia (CIAS). BACKGROUND OF THE INVENTIONSchizophrenia is a chronic devastating disorder, starting early in life and imposing a large health care burden in terms of hospitalisation, chronic treatment, and lost productivity, with treatment and care for schizophrenia patients accounting for between 1.5% and 3% of the total national health expense in the most developed countries [Altamura C, Galderisi P, Rocca A, et al. Ital J Psychopathol 2014; 20:223-43], [Knapp M, Mangalore R, Simon J. Schizophr Bull 2004; 30:279-93]. The global and societal burden of schizophrenia is large with the World Health Organization ranking it as the 12th most disabling disorder worldwide. Patients with schizophrenia have significantly lower life expectancy, and with suicide accounting for approximately 15% of deaths…